Department of Hepato-Biliary Surgery, Service de Chirurgie Hépato-Billaire, Hôpital Beaujon, Assistance-Publique Hôpitaux de Paris, Université Paris 7, Clichy, France.
Cancer. 2011 May 15;117(10):2170-7. doi: 10.1002/cncr.25712. Epub 2010 Nov 29.
This year, the 7th edition of the AJCC staging manual has for the first time attributed a unique pTNM staging to intrahepatic cholangiocarcinoma (IHCC) that is intended to replace the 2 Western and ideally also the 2 Eastern systems currently in use. This proposal, which has not yet been validated, was tested in the current study.
Among 522 patients operated on with curative intent for an IHCC between 1994 and 2008 in tertiary hepatobiliary centers, those with mass-forming-type IHCCs, an R0 resection, and accurate pathological node staging were retained for evaluation. The distribution of these patients and their actuarial survival in the new TNM stages (as well as in the 4 previous ones) were compared.
Only 163 patients fulfilled the inclusion criteria, mainly because of the lack of routine lymphadenectomy, but patients and tumors characteristics of this population were representative. These patients were evenly distributed between AJCC 7th edition stages (stage I, 28%; stage II, 32%; stage III, 35%), which was not the case for the other systems. With an average follow-up of 34 months in survivors, the AJCC 7th edition was more discriminating than the others in predicting survival (median for stage I not reached; for stage II, 53 months, P = .01; for stage III, 16 months, P < .0001). Survival of these patients according to the 2 Japanese classifications was identical to that anticipated.
The 7th edition is clinically relevant and may be applicable worldwide, provided routine lymphadenectomy at the time of surgery for IHCC becomes the standard of care.
今年,第 7 版 AJCC 分期手册首次为肝内胆管癌(IHCC)分配了独特的 pTNM 分期,旨在取代目前正在使用的 2 种西方系统和理想情况下的 2 种东方系统。该提议尚未得到验证,本研究对此进行了检验。
在 1994 年至 2008 年期间在三级肝胆中心接受根治性手术治疗的 522 例 IHCC 患者中,保留了具有肿块形成型 IHCC、R0 切除和准确病理淋巴结分期的患者进行评估。比较这些患者的分布及其在新 TNM 分期(以及前 4 个分期)中的累积生存率。
只有 163 例患者符合纳入标准,主要是由于缺乏常规淋巴结切除术,但该人群的患者和肿瘤特征具有代表性。这些患者在 AJCC 第 7 版分期(I 期 28%,II 期 32%,III 期 35%)中分布均匀,而其他系统并非如此。在幸存者中平均随访 34 个月,AJCC 第 7 版在预测生存方面比其他版本更具鉴别力(I 期的中位未达到;II 期为 53 个月,P=0.01;III 期为 16 个月,P<0.0001)。这些患者根据 2 种日本分类的生存率与预期一致。
第 7 版具有临床相关性,并且可以在全球范围内应用,前提是在进行 IHCC 手术时常规进行淋巴结切除术成为护理标准。